Table II. Predictors of OS and PFS in Univariate Analysis (n = 48).
| Median OS, months | Overall survival | Median DFS, months | Progression-free survival | |
|---|---|---|---|---|
| Primary melanoma type | ||||
| Cutaneous | 22 | ns | ns | |
| Ocular | 27.2 | |||
| Sex | ||||
| Male | 26 | ns | 11 | ns |
| Female | 18 | 9 | ||
| Age | ||||
| <60 years | 17.4 | 0.03 | 11 | 0.09 |
| >60 years | 27.2 | 0.07 | 12.1 | 0.07 |
| Primary to liver metastases interval, months | 0.19 | 0.19 | ||
| Preoperative LDH level > 400U/l | ||||
| Yes | 18 | ns | 4 | ns |
| No | 22 | 10 | ||
| Preoperative therapy | ||||
| Yes | 36 | ns | 11 | ns |
| No | 20 | 10 | ||
| EHD | ||||
| Yes | 12 | 0.076 | 5 | 0.11 |
| No | 26.5 | 13 | ||
| Number of liver metastases | ||||
| Solitary | 27.2 | 0.16 | 12 | ns |
| Multiple | 17.4 | 0.16 | 4 | 0.13 |
| Largest liver metastases, cm | ns | ns | ||
| Postoperative therapy | ||||
| Yes | 20 | ns | 11 | ns |
| No | 36 | 11 | ||
EHD, extrahepatic disease; LDH, lactate dehydrogenase; ns, non significant with P > 0.2.